Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

医学 伦瓦提尼 贝伐单抗 索拉非尼 肿瘤科 阿替唑单抗 内科学 肝细胞癌 成本效益 癌症 化疗 无容量 风险分析(工程) 免疫疗法
作者
Hongyu Gong,Siew Chin Ong,Li Fan,Zhiying Weng,Keying Zhao,Zhengyou Jiang
出处
期刊:Cost Effectiveness and Resource Allocation [BioMed Central]
卷期号:21 (1) 被引量:5
标识
DOI:10.1186/s12962-023-00435-x
摘要

Abstract Background and Objective Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, especially in China. According to the 2021 Chinese Society of Clinical Oncology guidelines, sorafenib, lenvatinib, atezolizumab combined with bevacizumab, and sintilimab combined with bevacizumab are recommended as first-line treatment options for advanced HCC. This study provides a cost-effectiveness analysis of these treatments from the patient perspective. Methods A partitioned survival model was established using the TreeAge 2019 software to evaluate the cost-effectiveness. The model includes three states, namely progression-free survival, progressive disease, and death. Clinical data were derived from three randomized controlled studies involving patients with advanced HCC who received the following treatment: sorafenib and lenvatinib (NCT01761266); atezolizumab in combination with bevacizumab (NCT03434379); and sintilimab in combination with bevacizumab (NCT03794440). Cost and clinical preference data were obtained from the literature and interviews with clinicians. Results All compared with sorafenib therapy, lenvatinib had an incremental cost-effectiveness ratio (ICER) of US$188,625.25 per quality-adjusted life year (QALY) gained; sintilimab plus bevacizumab had an ICER of US$75,150.32 per QALY gained; and atezolizumab plus bevacizumab had an ICER of US$144,513.71 per QALY gained. The probabilistic sensitivity analysis indicated that treatment with sorafenib achieved a 100% probability of cost-effectiveness at a threshold of US$36,600/QALY. One-way sensitivity analysis revealed that the results were most sensitive to the medical insurance reimbursement ratio and drug prices. Conclusions In this economic evaluation, therapy with lenvatinib, sintilimab plus bevacizumab, and atezolizumab plus bevacizumab generated incremental QALYs compared with sorafenib; however, these regimens were not cost-effective at a willingness-to-pay threshold of US$36,600 per QALY. Therefore, some patients may achieve preferred economic outcomes from these three therapies by tailoring the regimen based on individual patient factors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
末末完成签到 ,获得积分10
6秒前
无为完成签到 ,获得积分10
7秒前
白嫖论文完成签到 ,获得积分10
9秒前
上官若男应助忧伤的步美采纳,获得10
12秒前
科研通AI2S应助科研通管家采纳,获得10
12秒前
15秒前
从心随缘完成签到 ,获得积分10
16秒前
花花发布了新的文献求助10
18秒前
牛奶面包完成签到 ,获得积分10
19秒前
20秒前
岁月如歌完成签到 ,获得积分0
20秒前
23秒前
Li完成签到,获得积分10
25秒前
张琨完成签到 ,获得积分10
25秒前
25秒前
sunnyqqz完成签到,获得积分10
28秒前
热情的乘风完成签到,获得积分20
28秒前
30秒前
霍凡白完成签到,获得积分10
31秒前
32秒前
Feng发布了新的文献求助20
33秒前
怕孤单的若颜完成签到 ,获得积分10
35秒前
36秒前
ruochenzu发布了新的文献求助10
39秒前
zhongu发布了新的文献求助10
43秒前
阳光彩虹小白马完成签到 ,获得积分10
43秒前
Feng完成签到,获得积分10
45秒前
花花完成签到,获得积分10
47秒前
50秒前
量子星尘发布了新的文献求助10
52秒前
杨一完成签到 ,获得积分10
55秒前
猫猫头完成签到 ,获得积分10
56秒前
58秒前
1分钟前
忒寒碜完成签到,获得积分10
1分钟前
1分钟前
XU博士完成签到,获得积分10
1分钟前
哭泣青烟完成签到 ,获得积分10
1分钟前
roundtree完成签到 ,获得积分0
1分钟前
等待谷南完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022